← Back to Search

CBG Treatment for Rheumatoid Arthritis

N/A
Waitlist Available
Research Sponsored by Raphael Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 2, week 4, week 6, and week 8
Awards & highlights
No Placebo-Only Group

Summary

This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.

Eligible Conditions
  • Inflammatory Diseases
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 2, week 4, week 6, and week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 2, week 4, week 6, and week 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in inflammatory markers from Baseline to Week 8
Secondary study objectives
Change in self-reported symptoms and quality of life from Baseline to Week 8

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CBG TreatmentExperimental Treatment1 Intervention
Participants will receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening for a duration of eight weeks.

Find a Location

Who is running the clinical trial?

Raphael PharmaLead Sponsor
CitruslabsIndustry Sponsor
89 Previous Clinical Trials
4,718 Total Patients Enrolled
~8 spots leftby Nov 2025